login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Frontline Therapy With Second Line Drug Holds Promise in Leukaemia
December 10, 2007 at 8:18 PM
Drug News
The results were declared in report at the 49th annual meeting of the American Society of Hematology.
In both the trials, after one year on either drug, all the patients had a complete cytogenetic response (absence of the aberrant chromosome that causes the disease).
Almost 90 pct reach complete cytogenetic response as early as 6 months.
"These are early results but certainly encouraging so far in both cases," said Dr. Cortes.
Patients in both trials had been in the chronic or initial phase, of CML and had not received prior therapy for their disease.
The two medications are dasatinib, the Bristol-Myers Squibb drug known as Sprycel(r), and nilotinib, the Novartis drug known as Tasigna(r).
Both the drugs have been approved by the U.S. Food and Drug Administration for use in CML patients whose disease becomes resistant to the frontline therapy imatinib, also a Novartis drug known as Gleevec(r), or who become intolerant to the drug.
Cortes and colleagues compared the two medications at 3, 6 and 12 months with historical data from patients who took either 400 mg or 800 mg daily of Gleevec.
|
|
|
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
|
|
- News Quick Links
| News Categories: |
| » | Rock Music at Concerts may Lead to Hearing Problems |
| » | Construction Of 'Intelligent' Robot That Designs Tools on Its Own |
| » | Social Media Helping in Sharing of Information Post Disasters |
| » | 88,000 Racism Incidents Reported in UK Schools Between 2007-2011 |
| » | Expenditure Of 118 Million To Improve Water Quality: Beijing |
| More Life Style News | |
|
